MedTrace Logo

Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1

NCT03518060 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 209

Last updated 2024-10-16

Study results available
· View outcomes & findings →

Summary

This was a prospective, non-interventional, single-arm, multi-center study aimed at gathering real-world data on JULUCA use in routine clinical care in Germany, to supplement clinical trial data to further improve/optimize care in HIV positive participants in Germany. Approximately 250 virologically suppressed HIV positive participants on stable antiretroviral therapy (ART) were included in the study at the discretion of treating physician. Eligible participants were followed up for approximately 3 years and data was collected during routine clinical care.

Conditions

  • HIV Infections

Interventions

DRUG

JULUCA

JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).

Sponsors & Collaborators

  • MUC Research GmbH

    collaborator OTHER

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-25
Primary Completion
2023-05-14
Completion
2023-05-14

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03518060 on ClinicalTrials.gov